

Amendments to the Claims:

This listing of claims will replace all previous versions and listings of claims in the application:

1. (currently amended) A method for inhibiting aberrant neuron sprouting *in vivo* a biological activity mediated by a neurotrophin receptor, comprising contacting a human trkC receptor of SEQ ID NO: 6 expressed in neuron cells said neurotrophin receptor with an antagonistic antibody specific for said neurotrophin receptor specifically binding to a sequence within amino acid residues 32 and 839 of SEQ ID NO: 6, wherein said neurotrophin receptor is selected from the group consisting of human trkA, human trkB and human trkC.
- 2.-3. canceled.
4. (original) The method of claim 1 wherein said antibody is a monoclonal antibody.
5. (original) The method of claim 1 wherein said antibody is an antibody fragment selected from the group consisting of Fab, Fa(ab'), F(ab')₂, and Fv.
6. (original) The method of claim 1 wherein said antibody is selected from monospecific antibodies, bispecific antibodies and heteroconjugate antibodies.
7. (original) The method of claim 1 wherein said antibody is a human antibody or a humanized antibody.
- 8-22. (canceled)
23. (currently amended) A method for the treatment of a pathological condition associated with elevated endogenous neurotrophin NT-3 production in a subject, comprising contacting treating said subject with a therapeutically effective amount of an antibody specific for the

neurotrophin receptor specifically binding to a sequence within amino acid residues 32 and 839 of SEQ ID NO: 6, wherein said neurotrophin receptor is selected from the group consisting of human trkB, human trkA and human trkC.

24.-25. (canceled)